Welcome to our dedicated page for Pharmacyte Biotech news (Ticker: PMCB), a resource for investors and traders seeking the latest updates and insights on Pharmacyte Biotech stock.
PharmaCyte Biotech, Inc. (NASDAQ: PMCB) generates news that spans biotechnology development, strategic investments, and corporate finance. The company has reported on its ongoing evaluation of the Cell-in-a-Box live-cell encapsulation technology for potential use in cancer, diabetes, and malignant ascites, as well as its plans to engage with the U.S. Food and Drug Administration for guidance on future development steps.
Recent press releases highlight PharmaCyte’s shift toward using its cash and marketable securities to support external opportunities. The company has announced a $5 million stake in Femasys Inc., a women’s health-focused biomedical company, and a $7 million strategic investment in MyMD Pharmaceuticals, Inc., which is developing therapies for age-related diseases and inflammatory and autoimmune conditions. PharmaCyte has also disclosed an increased investment in TNF Pharmaceuticals (later referenced as Q/C Technologies, Inc.) through preferred stock and warrants tied to a licensed light-based processing accelerator platform intended for compute-intensive applications.
Investors following PMCB news will also see updates on capital structure and balance sheet actions, including a cash tender offer to repurchase a substantial portion of its outstanding common stock, a private placement of convertible redeemable preferred stock and warrants that raised approximately $35 million, and a subsequent Series C convertible preferred stock financing with accompanying warrants. Company communications emphasize what management describes as a disciplined capital allocation strategy and efforts to strengthen its financial position.
This news page aggregates PharmaCyte’s announcements about technology evaluation, strategic investments, tender offers, preferred stock and warrant financings, and related stockholder and governance matters, providing a single stream of company-issued updates for PMCB shareholders and observers.
PharmaCyte Biotech, Inc. (NASDAQ: PMCB) announced that its pancreatic cancer trial product candidate, CypCaps™, has shown no systemic toxicity in recent studies. Conducted by a third-party organization, the study involved assessing empty cellulose sulphate capsules' toxicity in mice, aligning with FDA standards. Results confirmed that none of the test subjects exhibited clinical signs of toxicity, weight changes, or mortality. CEO Kenneth L. Waggoner emphasized the study's importance in validating the capsule's inert nature, supporting ongoing development of their targeted chemotherapy solution for pancreatic cancer.
PharmaCyte Biotech, Inc. (NASDAQ: PMCB) is accelerating preparations for its Phase 2b clinical trial focused on locally advanced, inoperable pancreatic cancer (LAPC) using CypCaps™. CEO Kenneth L. Waggoner highlighted the company's favorable study results and solid financial position, allowing for immediate preparations to enroll the first patient. Key tasks include finalizing trial protocols, reengaging contractors, and manufacturing syringes for the trial. This innovative therapy utilizes encapsulated cells to activate chemotherapy drugs at tumor sites, promising targeted treatment with minimal side effects.
PharmaCyte Biotech, Inc. (NASDAQ: PMCB) has appointed Dr. Matthias Löhr to its Board of Directors. Dr. Löhr, a leading expert in gastroenterology and oncology, is expected to enhance the company's strategic direction, especially as it approaches FDA clinical trials for pancreatic cancer. With a robust background in clinical trials and a history with PharmaCyte's technology, Dr. Löhr's involvement is anticipated to positively influence development efforts in cancer and diabetes therapies using the Cell-in-a-Box® technology.
PharmaCyte Biotech (NASDAQ: PMCB) has completed a crucial 24-month stability study for its clinical trial product candidate, CypCaps™, demonstrating a shelf life of at least 24 months at -80°C. This milestone confirms the product's viability, enzymatic activity, and cell potency, essential for its cancer therapy applications. CEO Kenneth Waggoner highlighted the study's significance for both PharmaCyte and the cell therapy sector. Data from this study will be included in PharmaCyte's updated submission to the FDA, further solidifying its position in developing cellular therapies for cancer and diabetes.
PharmaCyte Biotech (NASDAQ: PMCB) announced its Q3 financial results for the period ending January 31, 2022, revealing a cash position of approximately
PharmaCyte Biotech, Inc. (NASDAQ: PMCB) has announced a detailed analysis of the integration site of the cytochrome P450 2B1 gene in its pancreatic cancer product candidate, CypCaps™. Previous studies indicated the gene was located on human chromosome 9. The new findings confirm the structure of the transgene sequence and demonstrate genetic stability in cell growth. PharmaCyte aims to develop cellular therapies for cancer and diabetes using its Cell-in-a-Box® technology, which has been effective in previous clinical trials.
PharmaCyte Biotech (NASDAQ: PMCB) provided an update on its efforts to lift the FDA's clinical hold on its treatment for locally advanced pancreatic cancer. Following an Investigational New Drug Application, the FDA requested additional studies. PharmaCyte has completed several studies and is actively engaging with experts and organizations to compile required data. Challenges include global supply chain issues affecting study timelines. Key updates include the addition of regulatory expertise, successful completion of product stability studies, and commencement of various biocompatibility studies.
PharmaCyte Biotech (NASDAQ: PMCB) announced its participation as a presenting company at the virtual H.C. Wainwright BioConnect Conference from January 10-13, 2022. CEO Kenneth L. Waggoner will discuss the company's business and product pipeline during the presentation, available on-demand starting January 10, 2022. Additionally, PharmaCyte plans to release an update on its clinical hold by the FDA for its Phase 2b trial targeting locally advanced pancreatic cancer. More information is available on their website.
PharmaCyte Biotech (NASDAQ: PMCB) announced findings from a recent study confirming that the capsule material in its CypCaps pancreatic cancer product is non-toxic to encapsulated cells. The evaluation showed the capsule material is bio-inert, supporting treatment for locally advanced, inoperable pancreatic cancer. Conducted in compliance with international standards, the study used mouse fibroblast cells to assess cytotoxicity, yielding positive results. This adds to PharmaCyte's goal of developing effective cancer and diabetes therapies using its unique Cell-in-a-Box technology.
PharmaCyte Biotech (NASDAQ: PMCB) has completed a significant 36-month stability study of cells from its Master Cell Bank, crucial for its treatment of locally advanced pancreatic cancer (LAPC). This study, required by the FDA to lift a clinical hold on its CypCaps product, confirms that the cells are stable and viable when stored in liquid nitrogen. The ongoing research will continue to assess the maximum shelf life of these cells. PharmaCyte plans to include findings from this study in its Complete IND Submission to the FDA.
FAQ
What is the current stock price of Pharmacyte Biotech (PMCB)?
What is the market cap of Pharmacyte Biotech (PMCB)?
